Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series
Abstract
The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant toxicity lacks evidence-based guidance.
Journal details
Journal Cancer Immunology, Immunotherapy
Volume 66
Issue number 1
Pages 113-117
Available online
Publication date
Full text links
Publisher website (DOI) 10.1007/s00262-016-1926-2
Europe PubMed Central 27838762
Pubmed 27838762